Adaptive Biotechnologies to receive up to $250M in financing deal

The Seattle-based biotech can tap three tranches of funding under an agreement with health care investment firm OrbiMed.
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.